tj004309
mAbexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Apr 12, 2019 (NCT03835949)
Timeline
Indications
Mechanism of action
- 5'-nucleotidaseINHIBITOR
NT5E inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650519 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07005336 | Phase 2 | Jan 9, 2025 | — |
| NCT06984588 | Phase 2/Phase 3 (Phase 3) | Mar 28, 2024 | — |
| NCT05001347 | Phase 2 | Oct 31, 2021 | I-Mab Biopharma |
| NCT04322006 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2020 | I-Mab Biopharma |
| NCT03835949 | Phase 1 | Apr 12, 2019 | Tracon Pharmaceuticals Inc. |
| NCT04869501 | N/A | — | I-Mab Biopharma |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| I-Mab Biopharma | For profit | 3 | 3 | 2 | 2020 |
| Tracon Pharmaceuticals Inc. | For profit | 1 | 1 | 1 | 2019 |
2 organizations
Page 1 / 1